As of November 2014, a Phase 2, multi-centre, open-label study was recruiting newly diagnosed Wilson's disease patients 18 and older to evaluate the efficacy and safety of bis-choline tetrathiomolybdate administration over a 24-week period. As of 2016, tetrathiomolybdate had been tested in over 500 patients for up to seven years, primarily in oncology and Wilson's disease, as well as some other clinical pathologies. The data suggest that bis-choline tetrathiomolybdate can rapidly lower and control toxic free copper levels and improve clinical symptoms in Wilson's disease patients. The data also suggest that it is generally well tolerated, with the potential for a reduced risk of neurological worsening after initiation of therapy compared to existing therapies.
Tiomolibdic acid
Tricresyl phosphate
Penicilloic acid
Disufenton sodium
Dimethyl methylphosphonate
Gadobenic acid
Sucroferric oxyhydroxide
Theramine